Related Experiment Video
Updated: Oct 13, 2026

Colon Ascendens Stent Peritonitis (CASP) - a Standardized Model for Polymicrobial Abdominal Sepsis
Published on: December 18, 2010
Ceftriaxone in the treatment of spontaneous bacterial peritonitis: ascitic fluid polymorphonuclear count response and
M A Mesquita1, E P Balbino, R S Albuquerque
1Department of Medicine, University of Campinas, Brazil.
Background/Aims:
In this study, ascitic fluid polymorphonuclear (PMN) response, short-term prognosis, and factors related to hospital mortality were investigated in 62 cases of spontaneous bacterial peritonitis occurring in cirrhotic patients treated with Ceftriaxone (1g every 12 hours).
Methodology:
The diagnostic criteria for (SBP) were ascitic fluid PMN count < 250 cells/mm3 and no evidence of secondary peritonitis. Analysis of ascitic fluid samples were obtained on admission, and on the 4th and 10th days of antibiotic therapy.
Results:
The etiology of cirrhosis was alcohol in 63% of the cases, and 79.5% of patients belonged to Child-Pugh Class C. Ascitic fluid analysis showed positive cultures in 47% of the cases, and a marked decrease in PMN count during treatment (admission: 7762 +/- 2837; 4th day: 388 +/- 91; 10th day: 173 +/- 59 cells/mm3). Ascitic PMN was < 250 cells/mm3 within 4 days of treatment in 33% of the cases. The hospital mortality rate was 24%, and was related to gastrointestinal hemorrhage, hepatic encephalopathy, renal failure and 4th day ascitic fluid PMN count.
Conclusion:
Ceftriaxone is a safe and effective option for the treatment of SBP.
Insights
Ceftriaxone effectively treats spontaneous bacterial peritonitis (SBP) in cirrhotic patients, reducing ascitic fluid polymorphonuclear cells and improving prognosis. Hospital mortality was linked to specific complications and PMN levels during treatment.
Area of Science:
- Hepatology
- Infectious Diseases
- Critical Care Medicine
Background:
- Spontaneous bacterial peritonitis (SBP) is a serious complication in cirrhotic patients.
- Alcohol-induced cirrhosis and advanced Child-Pugh Class C were common in the study population.
- Understanding SBP treatment response and mortality factors is crucial for patient outcomes.
Purpose of the Study:
- To evaluate the efficacy of Ceftriaxone in treating SBP in cirrhotic patients.
- To assess the ascitic fluid polymorphonuclear (PMN) response to Ceftriaxone therapy.
- To identify factors associated with hospital mortality in SBP patients.
Main Methods:
- A study of 62 cirrhotic patients diagnosed with SBP.
- Treatment with Ceftriaxone (1g every 12 hours).
- Ascitic fluid analysis, including PMN counts, on admission, day 4, and day 10.
Main Results:
- Ceftriaxone treatment led to a significant decrease in ascitic fluid PMN counts.
- 33% of patients achieved PMN counts below 250 cells/mm3 within 4 days.
- Hospital mortality rate was 24%, associated with gastrointestinal hemorrhage, hepatic encephalopathy, renal failure, and day 4 PMN count.
Conclusions:
- Ceftriaxone is a safe and effective antibiotic for treating SBP in cirrhotic patients.
- Early reduction in ascitic fluid PMN count may correlate with improved outcomes.
- Factors like hemorrhage, encephalopathy, and renal failure significantly impact mortality.
More Related Videos
Related Concept Videos
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
Acute Pyelonephritis II: Diagnostic Studies and Management
Rocky Mountain Spotted Fever

